128 related articles for article (PubMed ID: 35032074)
21. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
22. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.
Jacobs C; Tumati V; Kapur P; Yan J; Hong D; Bhuiyan M; Xie XJ; Pistenmaa D; Yu L; Hsieh JT; Saha D; Kim DW
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):729-35. PubMed ID: 24867541
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of transrectal ultrasound scan of the prostate with sector biopsies for 323 New Zealand men with suspicion of prostate cancer.
Smart R
N Z Med J; 1999 Dec; 112(1101):465-9. PubMed ID: 10678211
[TBL] [Abstract][Full Text] [Related]
24. HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
Wang J; He C; Gao P; Wang S; Lv R; Zhou H; Zhou Q; Zhang K; Sun J; Fan C; Ding G; Lan F
Oncogene; 2020 Feb; 39(6):1335-1346. PubMed ID: 31636385
[TBL] [Abstract][Full Text] [Related]
25. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
[TBL] [Abstract][Full Text] [Related]
26. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
27. Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery.
Li K; Chen MK; Situ J; Huang WT; Su ZL; He D; Gao X
Chin Med J (Engl); 2013 Jan; 126(1):82-7. PubMed ID: 23286483
[TBL] [Abstract][Full Text] [Related]
28. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.
Panousis D; Patsouris E; Lagoudianakis E; Pappas A; Kyriakidou V; Voulgaris Z; Xepapadakis G; Manouras A; Athanassiadou AM; Athanassiadou P
Eur J Gynaecol Oncol; 2011; 32(2):156-9. PubMed ID: 21614903
[TBL] [Abstract][Full Text] [Related]
29. Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy.
Gunnarsson O; Schelin S; Brudin L; Carlsson S; Damber JE
Scand J Urol; 2019; 53(2-3):102-108. PubMed ID: 30990112
[No Abstract] [Full Text] [Related]
30. Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging.
Linder BJ; Kawashima A; Woodrum DA; Tollefson MK; Karnes J; Davis BJ; Rangel LJ; King BF; Mynderse LA
Can J Urol; 2014 Jun; 21(3):7283-9. PubMed ID: 24978358
[TBL] [Abstract][Full Text] [Related]
31. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
32. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
[TBL] [Abstract][Full Text] [Related]
34. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
[TBL] [Abstract][Full Text] [Related]
35. Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.
Khedime S; Gelet A; Rouvière O; Lafon C; Badet L; Crouzet S; Hostiou T
J Urol; 2021 Aug; 206(2):325-337. PubMed ID: 33835863
[TBL] [Abstract][Full Text] [Related]
36. High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.
Steurer S; Rico SD; Simon R; Minner S; Tsourlakis MC; Krech T; Koop C; Graefen M; Heinzer H; Adam M; Huland H; Schlomm T; Sauter G; Lumiani A
BJU Int; 2017 Sep; 120(3):365-376. PubMed ID: 28295933
[TBL] [Abstract][Full Text] [Related]
37. [Clinical study of radical prostatectomy for prostate cancer from a single institution].
Ishida R; Kobayashi H; Yoshida S; Ogawa M; Shiota T; Nishikimi T; Yamada H; Yokoi K
Nihon Hinyokika Gakkai Zasshi; 2009 Sep; 100(6):615-24. PubMed ID: 19827538
[TBL] [Abstract][Full Text] [Related]
38. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
39. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
